4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
主营:主营:癌症、免疫、炎症、代谢疾病(糖尿病、肥胖)、干细胞和神经退行性疾病等领域
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > Other_reagents > Adipogen/OCH/AG-CR1-3593-M001/1 mg
商品详细Adipogen/OCH/AG-CR1-3593-M001/1 mg
Adipogen/OCH/AG-CR1-3593-M001/1 mg
Adipogen/OCH/AG-CR1-3593-M001/1 mg
商品编号: AG-CR1-3593-M001
品牌: Adipogen Inc
市场价: ¥4800.00
美元价: 2880.00
产地: 美国(厂家直采)
公司:
产品分类: 其他试剂
公司分类: Other_reagents
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍
MoreInformation
ProductDetails
Synonyms(2S,3S,4R)-1-O-(α-D-Galactopyranosyl)-N-tetracosanoyl-2-amino-1,3,4-nonanetriol)
ProductTypeChemical
Properties
FormulaC39H77NO9
MW704.0
CAS383187-82-4
PurityChemicals≥95%
AppearanceWhitetooff-whitesolid.
SolubilitySolubleinDMSO,100%ethanol(warm)ormethanol(warm).
InChiKeyMPKIDHIOYNMFES-CLTBVUQJSA-N
ShippingandHandling
ShippingBLUEICE
ShortTermStorage+4°C
LongTermStorage-20°C
HandlingAdviceAfterstandardreconstitution,preparealiquotsandstoreat-20°C.
Aliquotintoglassvials.
Use/StABIlityStableforatleast2yearsafterreceiptwhenstoredat-20°C.
Documents
MSDSDownloadPDF
ProductSpecificationSheet
DatasheetDownloadPDF
  • Truncatedanalogofα-GalCer.
  • iNKTcellglycolipidagoNIST.
  • Immunosuppressive.
  • Th2polarizing.StimulationofNKTwithOCHresultsinreleaseofprimarilyTh2cytokinecomparedtostimulationwithα-GalCer,whichresultsinreleaseofamixtureofTh1andTh2cytokines.
  • Inducesstrongerinterleukin-4(IL-4)secretionandweakerinterferon-γ(IFN-γ)secretionthanα-GalCerbothinvitroandinvivo.
  • Inducerofinterleukin-10(IL-10)andsuppressorofdiabetes.
  • Showntopreventexperimentalautoimmuneencephalomyelitis(EAE)inmice,ananimalmodelofmultiplesclerosis.
  • HasbeneficialeffectsontypeIdiabetesinNODmice.
  • Suppressorofcollagen-inducedarthritis.
  • Mightbeusefulforimmunotherapyoftransplantrejection.
ProductReferences
  1. AsyntheticglycolipidpreventsautoimmuneencephalomyelitisbyinducingTH2biasofnaturalkillerTcells:K.Miyamoto,etal.;Nature413,531(2001)
  2. SyntheticglycolipidOCHpreventsinsulitisanddiabetesinNODmice:M.Mizuno,etal.;J.Autoimmun.23,293(2004)
  3. TheclinicalimplicationandmolecularmechanismofpreferentialIL-4productionbymodifiedglycolipid-stimulatedNKTcells:S.Oki,etal.;J.Clin.Invest.113,1631(2004)
  4. Suppressionofcollagen-inducedarthritisbynaturalkillerTcellactivationwithOCH,asphingosine-truncatedanalogofalpha-galactosylceramide:A.Chiba,etal.;ArthritisRheum.50,305(2004)
  5. Totalsynthesisofanimmunosuppressiveglycolipid,(2S,3S,4R)-1-O-(alpha-d-galactosyl)-2-tetracosanoylamino-1,3,4-nonanetriol:K.Murata,etal.;J.Org.Chem.70,2398(2005)
  6. SynthesisandevaluationofsphinganineanaloguesofKRN7000andOCH:R.M.Ndonye,etal.;J.Org.Chem.70,10260(2005)
  7. IFN-γ–mediatednegativefeedbackregulationofNKT-cellfunctionbyCD94/NKG2:T.Ota,etal.;Blood106,184(2005)
  8. ModulationofCD1d-restrictedNKTcellresponsesbyusingN-acylvariantsofalpha-galactosylceramides:Y.KO,etal.;PNAS102,3383(2005)
  9. α-Galactosylceramidetherapyforautoimmunediseases:Prospectsandobstacles:L.VanKaer;Nat.Rev.Immunol.5,31(2005)
  10. GlycolipidsfornaturalkillerTcells:P.B.Savage,etal.;Chem.Soc.Rev.351,771(2006)
  11. ProlongationofcardiacallograftsurvivalbyrapamycinandtheinvariantnaturalkillerTcellglycolipidagonistOCH:S.M.Haeryfar,etal.;Transplantation86,460(2008)
  12. Mechanismsforglycolipidantigen-drivencytokinepolarizationbyValpha14iNKTcells:B.A.Sullivan,etal.;J.Immunol.184,141(2010)
  13. AmolecularbasisfortheexquisiteCD1d-restrictedAntigen-specificityandfunctionalresponsesofNaturalKillerTcells:K.S.Wun,etal.;Immunity34,327(2011)
  14. Structuralandfunctionalcharacterizationofanovelnon-glycosidiciNKTagonistwithimmunomodulatoryproperties:J.Kerzerho,etal.;J.Immunol.188,2254(2012)
  15. SynthesisandBIOLOGicalactivityofhydroxylatedanaloguesofKRN7000(α-galactosylceramide):M.Shiozaki,etal.;Carbohydr.Res.370,46(2013)
  16. iNKTcellcytotoxicresponsescontrolT-lymphomagrowthinvitroandinvivo:H.Bassiri,etal.;CancerImmunol.Res.2,59(2014)
  17. ImpactofTh1/Th2cytokinepolarityinducedbyinvariantNKTcellsontheincidenceofpregnancylossinmice:M.Hoya,etal.;Am.J.Reprod.Immunol.aheadofprint(2018)
品牌介绍
Adipogen公司由三个子公司组成,分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国,运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发,如癌症、免疫、炎症、代谢疾病(糖尿病、肥胖)、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外,也可提供抗体和蛋白产品,Adipogen拥有自己的化学实验室,致力于开发创新型小分子化合物。